Analytic, preanalytic, and clinical validation of p53 IHC for detection of TP53 missense mutation in prostate cancer

Liana B. Guedes, Fawaz Almutairi, Michael C. Haffner, Gaurav Rajoria, Zach Liu, Szczepan Klimek, Roberto Zoino, Kasra Yousefi, Rajni Sharma, Angelo M. De Marzo, George J. Netto, William B. Isaacs, Ashley E. Ross, Edward M. Schaeffer, Tamara L. Lotan

Research output: Research - peer-reviewArticle

Abstract

Purpose: TP53 missense mutations may help to identify prostate cancer with lethal potential. Here, we preanalytically, analytically, and clinically validated a robust IHC assay to detect subclonal and focal TP53 missense mutations in prostate cancer. Experimental Design: The p53 IHC assay was performed in a CLIA-accredited laboratory on the Ventana Benchmark immunostaining system. p53 protein nuclear accumulation was defined as any p53 nuclear labeling in >10% of tumor cells. Fifty-four formalin-fixed paraffin embedded (FFPE) cell lines from the NCI-60 panel and 103 FFPE prostate cancer tissues (88 primary adenocarcinomas, 15 metastases) with known TP53 mutation status were studied. DU145 and VCaP xenografts were subjected to varying fixation conditions to investigate the effects of preanalytic variables. Clinical validation was performed in two partially overlapping radical prostatectomy cohorts. Results: p53 nuclear accumulation by IHC was 100% sensitive for detection of TP53 missense mutations in the NCI-60 panel (25/25 missense mutations correctly identified). Lack of p53 nuclear accumulation was 86% (25/29) specific for absence of TP53 missense mutation. In FFPE prostate tumors, the positive predictive value of p53 nuclear accumulation for underlying missense mutation was 84% (38/45), whereas the negative predictive value was 97% (56/58). In a cohort of men who experienced biochemical recurrence after RP, the multivariable HR for metastasis among cases with p53 nuclear accumulation compared with those without was 2.55 (95% confidence interval, 1.1–5.91). Conclusions: IHC is widely available method to assess for the presence of deleterious and heterogeneous TP53 missense mutations in clinical prostate cancer specimens.

LanguageEnglish (US)
Pages4693-4703
Number of pages11
JournalClinical Cancer Research
Volume23
Issue number16
DOIs
StatePublished - Aug 15 2017

Fingerprint

Missense Mutation
Prostatic Neoplasms
Paraffin
Formaldehyde
Neoplasm Metastasis
Neoplasms
Benchmarking
Prostatectomy
Nuclear Proteins
Heterografts
Prostate
Adenocarcinoma
Research Design
Confidence Intervals
Recurrence
Cell Line
Mutation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Analytic, preanalytic, and clinical validation of p53 IHC for detection of TP53 missense mutation in prostate cancer. / Guedes, Liana B.; Almutairi, Fawaz; Haffner, Michael C.; Rajoria, Gaurav; Liu, Zach; Klimek, Szczepan; Zoino, Roberto; Yousefi, Kasra; Sharma, Rajni; De Marzo, Angelo M.; Netto, George J.; Isaacs, William B.; Ross, Ashley E.; Schaeffer, Edward M.; Lotan, Tamara L.

In: Clinical Cancer Research, Vol. 23, No. 16, 15.08.2017, p. 4693-4703.

Research output: Research - peer-reviewArticle

Guedes, LB, Almutairi, F, Haffner, MC, Rajoria, G, Liu, Z, Klimek, S, Zoino, R, Yousefi, K, Sharma, R, De Marzo, AM, Netto, GJ, Isaacs, WB, Ross, AE, Schaeffer, EM & Lotan, TL 2017, 'Analytic, preanalytic, and clinical validation of p53 IHC for detection of TP53 missense mutation in prostate cancer' Clinical Cancer Research, vol 23, no. 16, pp. 4693-4703. DOI: 10.1158/1078-0432.CCR-17-0257
Guedes LB, Almutairi F, Haffner MC, Rajoria G, Liu Z, Klimek S et al. Analytic, preanalytic, and clinical validation of p53 IHC for detection of TP53 missense mutation in prostate cancer. Clinical Cancer Research. 2017 Aug 15;23(16):4693-4703. Available from, DOI: 10.1158/1078-0432.CCR-17-0257
Guedes, Liana B. ; Almutairi, Fawaz ; Haffner, Michael C. ; Rajoria, Gaurav ; Liu, Zach ; Klimek, Szczepan ; Zoino, Roberto ; Yousefi, Kasra ; Sharma, Rajni ; De Marzo, Angelo M. ; Netto, George J. ; Isaacs, William B. ; Ross, Ashley E. ; Schaeffer, Edward M. ; Lotan, Tamara L./ Analytic, preanalytic, and clinical validation of p53 IHC for detection of TP53 missense mutation in prostate cancer. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 16. pp. 4693-4703
@article{4aaf6a62f6de4a6d9fb0d8c187895b1d,
title = "Analytic, preanalytic, and clinical validation of p53 IHC for detection of TP53 missense mutation in prostate cancer",
abstract = "Purpose: TP53 missense mutations may help to identify prostate cancer with lethal potential. Here, we preanalytically, analytically, and clinically validated a robust IHC assay to detect subclonal and focal TP53 missense mutations in prostate cancer. Experimental Design: The p53 IHC assay was performed in a CLIA-accredited laboratory on the Ventana Benchmark immunostaining system. p53 protein nuclear accumulation was defined as any p53 nuclear labeling in >10% of tumor cells. Fifty-four formalin-fixed paraffin embedded (FFPE) cell lines from the NCI-60 panel and 103 FFPE prostate cancer tissues (88 primary adenocarcinomas, 15 metastases) with known TP53 mutation status were studied. DU145 and VCaP xenografts were subjected to varying fixation conditions to investigate the effects of preanalytic variables. Clinical validation was performed in two partially overlapping radical prostatectomy cohorts. Results: p53 nuclear accumulation by IHC was 100% sensitive for detection of TP53 missense mutations in the NCI-60 panel (25/25 missense mutations correctly identified). Lack of p53 nuclear accumulation was 86% (25/29) specific for absence of TP53 missense mutation. In FFPE prostate tumors, the positive predictive value of p53 nuclear accumulation for underlying missense mutation was 84% (38/45), whereas the negative predictive value was 97% (56/58). In a cohort of men who experienced biochemical recurrence after RP, the multivariable HR for metastasis among cases with p53 nuclear accumulation compared with those without was 2.55 (95% confidence interval, 1.1–5.91). Conclusions: IHC is widely available method to assess for the presence of deleterious and heterogeneous TP53 missense mutations in clinical prostate cancer specimens.",
author = "Guedes, {Liana B.} and Fawaz Almutairi and Haffner, {Michael C.} and Gaurav Rajoria and Zach Liu and Szczepan Klimek and Roberto Zoino and Kasra Yousefi and Rajni Sharma and {De Marzo}, {Angelo M.} and Netto, {George J.} and Isaacs, {William B.} and Ross, {Ashley E.} and Schaeffer, {Edward M.} and Lotan, {Tamara L.}",
year = "2017",
month = "8",
doi = "10.1158/1078-0432.CCR-17-0257",
volume = "23",
pages = "4693--4703",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Analytic, preanalytic, and clinical validation of p53 IHC for detection of TP53 missense mutation in prostate cancer

AU - Guedes,Liana B.

AU - Almutairi,Fawaz

AU - Haffner,Michael C.

AU - Rajoria,Gaurav

AU - Liu,Zach

AU - Klimek,Szczepan

AU - Zoino,Roberto

AU - Yousefi,Kasra

AU - Sharma,Rajni

AU - De Marzo,Angelo M.

AU - Netto,George J.

AU - Isaacs,William B.

AU - Ross,Ashley E.

AU - Schaeffer,Edward M.

AU - Lotan,Tamara L.

PY - 2017/8/15

Y1 - 2017/8/15

N2 - Purpose: TP53 missense mutations may help to identify prostate cancer with lethal potential. Here, we preanalytically, analytically, and clinically validated a robust IHC assay to detect subclonal and focal TP53 missense mutations in prostate cancer. Experimental Design: The p53 IHC assay was performed in a CLIA-accredited laboratory on the Ventana Benchmark immunostaining system. p53 protein nuclear accumulation was defined as any p53 nuclear labeling in >10% of tumor cells. Fifty-four formalin-fixed paraffin embedded (FFPE) cell lines from the NCI-60 panel and 103 FFPE prostate cancer tissues (88 primary adenocarcinomas, 15 metastases) with known TP53 mutation status were studied. DU145 and VCaP xenografts were subjected to varying fixation conditions to investigate the effects of preanalytic variables. Clinical validation was performed in two partially overlapping radical prostatectomy cohorts. Results: p53 nuclear accumulation by IHC was 100% sensitive for detection of TP53 missense mutations in the NCI-60 panel (25/25 missense mutations correctly identified). Lack of p53 nuclear accumulation was 86% (25/29) specific for absence of TP53 missense mutation. In FFPE prostate tumors, the positive predictive value of p53 nuclear accumulation for underlying missense mutation was 84% (38/45), whereas the negative predictive value was 97% (56/58). In a cohort of men who experienced biochemical recurrence after RP, the multivariable HR for metastasis among cases with p53 nuclear accumulation compared with those without was 2.55 (95% confidence interval, 1.1–5.91). Conclusions: IHC is widely available method to assess for the presence of deleterious and heterogeneous TP53 missense mutations in clinical prostate cancer specimens.

AB - Purpose: TP53 missense mutations may help to identify prostate cancer with lethal potential. Here, we preanalytically, analytically, and clinically validated a robust IHC assay to detect subclonal and focal TP53 missense mutations in prostate cancer. Experimental Design: The p53 IHC assay was performed in a CLIA-accredited laboratory on the Ventana Benchmark immunostaining system. p53 protein nuclear accumulation was defined as any p53 nuclear labeling in >10% of tumor cells. Fifty-four formalin-fixed paraffin embedded (FFPE) cell lines from the NCI-60 panel and 103 FFPE prostate cancer tissues (88 primary adenocarcinomas, 15 metastases) with known TP53 mutation status were studied. DU145 and VCaP xenografts were subjected to varying fixation conditions to investigate the effects of preanalytic variables. Clinical validation was performed in two partially overlapping radical prostatectomy cohorts. Results: p53 nuclear accumulation by IHC was 100% sensitive for detection of TP53 missense mutations in the NCI-60 panel (25/25 missense mutations correctly identified). Lack of p53 nuclear accumulation was 86% (25/29) specific for absence of TP53 missense mutation. In FFPE prostate tumors, the positive predictive value of p53 nuclear accumulation for underlying missense mutation was 84% (38/45), whereas the negative predictive value was 97% (56/58). In a cohort of men who experienced biochemical recurrence after RP, the multivariable HR for metastasis among cases with p53 nuclear accumulation compared with those without was 2.55 (95% confidence interval, 1.1–5.91). Conclusions: IHC is widely available method to assess for the presence of deleterious and heterogeneous TP53 missense mutations in clinical prostate cancer specimens.

UR - http://www.scopus.com/inward/record.url?scp=85028042524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028042524&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-0257

DO - 10.1158/1078-0432.CCR-17-0257

M3 - Article

VL - 23

SP - 4693

EP - 4703

JO - Clinical Cancer Research

T2 - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 16

ER -